Precision Optics Corporation, Inc. (POCI) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals record-high quarterly revenue and a significant increase in production revenue, despite a decline in gross margin. The Q&A section confirms conservative but optimistic guidance, with expectations of improved gross margins and a well-prepared pipeline. Management's clear responses and strategic focus on production and engineering projects suggest a positive outlook. The stock price is likely to react positively, with potential gains of 2% to 8% over the next two weeks.
Key Financial Performance
Quarterly Revenue $6.2 million in Q4 FY2025, the highest in the company's history, compared to $4.7 million in Q4 FY2024. This represents a year-over-year increase of approximately 32%. The increase was driven by the transition of two major programs from development to production.
Annual Revenue $19.1 million for FY2025, flat compared to FY2024. The flat growth masks a transformation from an engineering-focused business to a manufacturing enterprise.
Production Revenue $5.1 million in Q4 FY2025, compared to $2.8 million in Q4 FY2024, an increase of approximately 82%. This growth was driven by increased production from two major programs.
Engineering Revenue $1.1 million in Q4 FY2025, compared to $1.9 million in Q4 FY2024, a decrease of approximately 42%. The decline was due to the transition of the single-use cystoscope program to production.
Gross Margin 13% in Q4 FY2025, compared to 22% in Q4 FY2024. The decline was due to suboptimal yields in the single-use cystoscope production and under-absorption of engineering resources.
Net Loss $1.4 million in Q4 FY2025, flat compared to Q4 FY2024. The loss was influenced by increased SG&A expenses and suboptimal production yields.
Adjusted EBITDA Negative $856,000 in Q4 FY2025, compared to negative $1.1 million in Q4 FY2024. The improvement was due to increased production revenue.
Cash $1.8 million at the end of June 2025, with debt below $1.9 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Two major production programs: Transitioned from development to production, driving record revenues. One program is with a top-tier aerospace company, and the other is with a surgical robotics company focused on urology.
Unity platform: Launched to build a strong backlog of programs and expand the product development pipeline.
Market expansion through new facilities: Moved headquarters to Littleton, Massachusetts, and opened a new facility in South Portland, Maine, to support growth and access a broader engineering talent pool.
Gross margin challenges: Faced challenges in Q3 and Q4 of fiscal 2025 due to production yield issues, labor costs, and tariff increases. Steps are being taken to improve margins in fiscal 2026.
Operational investments: Hired new manufacturing and quality engineers, a Director of Quality and Regulatory Affairs, and a new Chief Operating Officer to improve manufacturing efficiency.
Strategic shift to production focus: Shifted from an engineering-focused business to a production-driven enterprise, with production revenue expected to grow by 75% in fiscal 2026.
Long-term contracts: Secured long-term contracts with minimum annual commitments for major programs, providing revenue visibility and stability.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Gross Margin Challenges: The company faced gross margin challenges in Q3 and Q4 of fiscal 2025 due to production yield issues, higher labor touch time, and substantial tariff increases. These challenges led to zero or negative gross margins for certain products, significantly impacting overall profitability.
Production Yield Issues: The single-use cystoscope program faced production yield challenges, resulting in higher costs and lower profitability. Design updates and process improvements are planned but will take months to implement.
Tariff Costs: Substantial tariff increases in Q3 and Q4 of fiscal 2025 negatively impacted gross margins, with Q4 tariff costs alone amounting to approximately $180,000, representing about 3% of gross margin.
Engineering Resource Allocation: Engineering resources were diverted to troubleshoot production issues, reducing the capacity for billable product development work and impacting overall gross margins.
Dependence on Major Programs: The company’s revenue growth is heavily reliant on two major production programs. Any disruption in these programs could significantly impact financial performance.
Operational Scaling Challenges: The company is transitioning from a small engineering-focused business to a larger manufacturing enterprise, facing challenges in scaling operations efficiently.
Debt and Cash Flow: The company has limited cash reserves of $1.8 million and debt of $1.9 million, necessitating efforts to increase debt capital to fund business expansion.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: The company projects fiscal 2026 revenues to reach $25 million, a 30% increase from $19 million in fiscal 2025. This growth is driven by the expansion of the systems manufacturing business, which is expected to grow by 75% from $8.3 million in fiscal 2025 to $14.5 million in fiscal 2026.
Gross Margin Projections: Gross margins are expected to recover to approximately 30% in fiscal 2026, compared to 18% in fiscal 2025. Improvements are anticipated due to better manufacturing yields, tariff reimbursements, and elimination of low-margin revenue.
Production Program Growth: The company expects continued revenue growth from its two major production programs. The aerospace program backlog stands at nearly $9 million, with commitments to double delivery rates. The single-use cystoscope program is expected to see steadily increasing profitability throughout fiscal 2026 due to design and production changes and renegotiated pricing.
Product Development Pipeline: The company anticipates two to three programs to transfer to production in each of the next two years, with a recovery in product development revenue from $4.9 million in fiscal 2025 to $5.6 million in fiscal 2026.
Operational Investments: Investments in facilities and personnel, including a new Chief Operating Officer and quality engineers, are expected to support long-term growth and operational efficiency.
Adjusted EBITDA: The company expects to recover positive adjusted EBITDA in the range of $0.5 million for fiscal 2026, driven by significant increases in revenue and gross margins.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Are you being conservative in your revenue guidance for 2026, given the expected increase in contributions from your two largest customers and higher engineering revenues?
A:Yes, we are being a little conservative. One business unit, our micro optics lab, will see a revenue decrease of about $800,000 due to the timing of a big order. Additionally, $0.5 million in Q4 revenue from tooling and fixturing will be replaced by higher-margin production revenue, especially from the aerospace program.
Q:How does your company benefit from charging capital costs to customers?
A:We charge a small markup on capital costs, which is low risk and pass-through. This benefits the bottom line but artificially reduces the gross margin percentage.
Q:How will the ramp-down of higher costs for the medical program work?
A:It’s a combination. We have open book pricing and negotiated margins. The customer agreed to cover higher start-up costs temporarily. We’ve negotiated a step-down in pricing with targets for resolving near-term problems, ultimately returning to the originally negotiated margins.
Q:What is the status of tariff-related price hikes?
A:We have verbal agreements in place and are in the process of documenting them.
Q:Are your engineering resources now available for new engineering revenue?
A:Generally, yes. While some redesign work for yield improvement will still require engineering resources, the amount of sustaining engineering work has significantly reduced. We’ve also hired a manufacturing engineer and a quality engineer to handle line issues, freeing up design engineers for new projects.
Q:Do you have projects lined up for your engineering team?
A:Yes, we have 7-8 programs in the pipeline, with three in the verification validation phase, which is just before production. We are also actively bringing in more programs and expect to have plenty of work for the engineering team.
Q:Does your company generate revenue as soon as engineers start working on a project?
A:Yes, we start billing as soon as engineers begin working on a project.
Q:Will the focus on the cystoscope program affect incoming production orders?
A:No, despite focusing on the cystoscope program, other programs have continued to progress. Three programs are in the verification validation phase and are expected to enter production within 12 months. Additionally, a laparoscope program will resume production later this year after addressing yield issues and relocating its production line.
Q:What is the status of the second single-use program?
A:The program is progressing well, with production starting in March-April. It is ramping more slowly than the cystoscope program, allowing smoother development. Lessons from the cystoscope program are being applied to address start-up challenges. The customer recently doubled their forecast, and the team is prepared for a smoother ramp-up.
Q:Will Q4 gross margins next year exceed 30%?
A:Yes, gross margins are expected to strengthen throughout the year, with Q4 margins well north of 30% due to improvements in the cystoscope line and the ramping of the aerospace program.
Q:Review of Unclear Management Responses
A:None of the questions were avoided or lacked clarity. All responses were detailed and addressed the questions directly.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Director
Littleton
Unity platform
addition
backlog
challenge step
commitment
cystoscope production
cystoscope program
debt
demand customer
development year
driver
expansion
foundation
history
improvement
increase line
line increase
manufacturing production
margin challenge
material
outreach
percentage
price end
pricing
production contract
production demand
production line
production revenue
profitability product
program challenge
recovery product
reduction
system manufacturing
tariff increase
tariff reimbursement
tier aerospace
touch
trend
yield
POCI Transcript
Precision Optics Corporation, Inc. (POCI) Q3 2026 Earnings Call Transcript
Positive5-13
The company increased revenue guidance, expects strong future growth, and achieved breakeven this quarter. Despite a temporary slowdown in aerospace, other programs are expected to offset this. The Q&A reveals positive sentiment from analysts, who are reassured by management's long-term growth plans and profitability expectations. The company's strategic developments, such as the Unity platform and facility expansions, further bolster a positive outlook. Overall, these factors suggest a positive stock price movement over the next two weeks.
Precision Optics Corporation, Inc. (POCI) Q2 2026 Earnings Call Transcript
Unknown2-17
Despite some positive developments in the aerospace and cystoscope programs, the company faces significant challenges. Declining gross margins, increased net loss, and negative EBITDA signal financial strain. The Q&A section revealed uncertainties about equity financing and loan success, which could lead to dilution. The strong demand and production improvements may not offset the immediate financial issues, leading to a negative sentiment and potential stock price decline.
Precision Optics Corporation, Inc. (POCI) Q1 2026 Earnings Call Transcript
Positive11-13
The earnings call indicates strong revenue growth, especially in key manufacturing programs, and an optimistic outlook for fiscal 2026 with improved gross margins and positive adjusted EBITDA. The Q&A section did not reveal significant negative trends, and the company's strategic expansion into defense aerospace alongside medical devices suggests diversification and potential profitability. Despite some concerns over gross margins and delayed orders, the overall sentiment is positive, supported by strong revenue expectations and strategic operational investments.
Precision Optics Corporation, Inc. (POCI) Q4 2025 Earnings Call Transcript
Positive9-29
The earnings call reveals record-high quarterly revenue and a significant increase in production revenue, despite a decline in gross margin. The Q&A section confirms conservative but optimistic guidance, with expectations of improved gross margins and a well-prepared pipeline. Management's clear responses and strategic focus on production and engineering projects suggest a positive outlook. The stock price is likely to react positively, with potential gains of 2% to 8% over the next two weeks.
POCI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
